Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Pipeline Insight Report 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Pipeline Insight, 2018’ report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)
The report assesses the active Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
3. Pipeline TherapeuticsAn Overview of Pipeline Products
4. Comparative Analysis
5. Pipeline Products in Clinical StagesProduct Description Research and Development Product Development Activities
6. Pipeline Products in Non-clinical StagesProduct Description Research and Development Product Development Activities
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline ProductsProduct Description Research and Development Product Development Activities Reason for dormancy/discontinuation
Companies MentionedAnGes MG Inc AstraZeneca Plc Athera Biotechnologies AB Athersys Inc Bayer AG Betagenon AB BiogenCell Ltd CardioVascular BioTherapeutics Inc Celgene Corp Diffusion Pharmaceuticals Inc Foresee Pharmaceuticals LLC Hemostemix Ltd ID Pharma Co Ltd Juventas Therapeutics Inc LipimetiX Development Inc miRagen Therapeutics Inc Novartis AG Nuo Therapeutics Inc Proteon Therapeutics Inc Recardio GmbH Resverlogix Corp Sigma-Tau SpA
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bdr88g/peripheral?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005744/en/
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/19/2018 03:10 PM/DISC: 12/19/2018 03:10 PM